XML 32 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

6 Months Ended

Dec. 31, 2016

Related Party Transactions [Abstract]

Schedule of Related Party Transactions [Table Text Block]

		For the three months ended								For the six months ended
		December 31,				December 31,				December 31,				December 31,
		2016				2015				2016				2015
Property and Equipment

During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company		$	-			$	6,747			$	17,995			$	14,648

		As of
		December 31,				June 30,
		2016				2016
Account Payable – Related Party

Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was		$	32,624			$	767,454

		For the three months ended								For the six months ended
		December 31,				December 31,				December 31,				December 31,
		2016				2015				2016				2015

Research and Development Costs Paid to Related Parties

Development fees and other costs charged by and paid to TheraCour pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at December 31, 2016 and June 30, 2016		$	978,501			$	996,398			$	1,840,116			$	2,012,614

		As of
		December 31,				June 30,
Debentures Payable to a Director		2016				2016

Series B Convertible Debentures - Milton Boniuk		$	4,000,000			$	4,000,000
Series C Convertible Debentures - Milton Boniuk			5,000,000				5,000,000

Total Debentures Payable to a Director		$	9,000,000			$	9,000,000

		As of
		December 31,				June 30,
Debenture Interest Payable to a Director		2016				2016

Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015:
Deferred interest payable - short-term		$	166,667			$	166,667
Deferred interest payable - long-term			83,333				166,667

Total Debenture Interest Payable to a Director		$	250,000			$	333,334